Last reviewed · How we verify
Peripheral nerve blocks with Bupivacaine
Peripheral nerve blocks with Bupivacaine, marketed by Mayo Clinic, is a well-established anesthetic solution in the healthcare sector. The key composition patent is set to expire in 2028, providing a significant period of market protection. The primary risk lies in potential competition once the patent expires, which could erode market share and revenue.
At a glance
| Generic name | Peripheral nerve blocks with Bupivacaine |
|---|---|
| Also known as | Marcaine, Sensorcaine |
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache (NA)
- Intercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatum (NA)
- Effectiveness of Thoracoabdominal Nerve Block (M-TAPA) on Postoperative Pain Relief in Laparoscopic Hysterectomy (NA)
- Efficacy of Nerve Blocks for Episodic Migraine (PHASE2)
- Subcostal Transversus Abdominus , Erector Spinae and Paravertebral Blocks Effects on Laparoscopic Cholecystectomy Cases (NA)
- Pericapsular Nerve Group Block Versus Intrathecal Morphine for Analgesia After Total Hip Arthroplasty (NA)
- Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study (NA)
- Peripheral Nerve Blocks and Postoperative Pain and Mobilization After Total Knee Arthroplasty
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peripheral nerve blocks with Bupivacaine CI brief — competitive landscape report
- Peripheral nerve blocks with Bupivacaine updates RSS · CI watch RSS
- Mayo Clinic portfolio CI